Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied DNA Sciences, Inc. - Common Stock (NQ:APDN)

0.8110 +0.0110 (+1.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Applied DNA Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Applied DNA Launches Initiatives to Expand Awareness of LinearDNA™ Platform as an Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website
From Applied DNA Sciences, Inc.
Via Business Wire
U.S. Government Guidance Permits DNA Traceability and Isotopic Testing as Evidence under Uyghur Forced Labor Prevention Act
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA and EvviVax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA™ Platform as a Novel Cancer Vaccine Strategy in the Journal of Experimental & Clinical Cancer Research
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Reports Second Quarter Fiscal 2022 Financial Results
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Schedules Fiscal 2022 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 12, 2022
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Awarded NYC-Based ‘Return-to-Office’
From Applied DNA Sciences, Inc
Via Business Wire
Applied DNA to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th – 30th from 9:00 a.m. - 5:00 p.m. EDT
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Executes LOI with Spindle Biotech for Research Collaboration on Simplified High Yield mRNA Production System
From Applied DNA Sciences, Inc. and Spindle Biotech Inc.
Via Business Wire
InvestorNewsBreaks — Applied DNA Sciences Inc. (NASDAQ: APDN) Closes on $4.2M Registered Direct Offering
Via Investor Brand Network
Applied DNA Announces Closing of $4.2 Million Registered Direct Offering
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Announces Pricing of $4.2 Million Registered Direct Offering
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA First Quarter Fiscal 2022 Financial Results Feature Record Quarterly Revenues
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Schedules Fiscal 2022 First Quarter Financial Results Conference Call and Webcast for Thursday, February 10, 2022
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA to Deploy Linea™ 1.0 COVID-19 Assay for Rapid Detection of New Omicron Subvariant BA.2
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Submits Request for Emergency Use Authorization to FDA for Linea™ 2.0 COVID-19 Assay and Linea™ Unsupervised At-Home Sample Collection Kit
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Announces Continued Momentum in COVID-19 Testing Demand
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Receives New York State Department of Health Conditional Approval for Linea™ 2.0 COVID-19 Assay as Laboratory Developed Test
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA and Stratum Reservoir (Isotech) Sign Memorandum of Understanding to Leverage Isotopic Analysis for Enhanced DNA-Based Cotton Authenticity and Provenance
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Reports Fourth Quarter and Full Fiscal Year 2021 Financial Results, Continuing Momentum in Diagnostic Testing
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Advances Cotton Genomics-based Methodology for Determination of Authenticity and Provenance
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Schedules Fourth Quarter and Full Fiscal Year 2021 Financial Results Conference Call and Webcast for Thursday, December 9, 2021
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Announces Strategy to Address Omicron SARS-CoV-2 Variant, Introduces Linea™ 2.0 COVID-19 Assay Kit
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer
From Applied DNA Sciences, Inc.
Via Business Wire
Research Publication Demonstrates Utility of Applied DNA’s LinearDNA™ in Non-Viral CAR T Manufacturing Systems
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Submits Request for Emergency Use Authorization to FDA for Linea™ SARS-CoV-2 Mutation Panel
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA and CLEARED4 Offer Fast, Cost-Effective and Turnkey Integrated Solution for Compliance with OSHA Mandate for COVID-19 Vaccination and Testing
From Applied DNA Sciences, Inc.
Via Business Wire
Ganesha Ecosphere and Applied DNA to Deploy CertainT® Platform to Secure Recycled Polyester Supply Chain
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Implements safeCircle™ COVID-19 Testing Program at Sarah Lawrence College
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Receives Purchase Orders Totaling $1.6 Million to Tag Textile Fibers
From Applied DNA Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.